The detection of IDH2 mutations can serve as a diagnostic marker. For example, in the context of AML, the presence of an IDH2 mutation can help differentiate between subtypes of leukemia and may guide the choice of treatment strategies. Techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are commonly used to identify these mutations in clinical samples.
